(25)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A2

(51) International Patent Classification[7]: C12N 15/00

(21) International Application Number: PCT/EP00/13149

(22) International Filing Date:
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB

(71) Applicant *(for all designated States except US)*: **DEVGEN NV** [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PLAETINCK, Geert** [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). **MORTIER, Katherine** [BE/BE]; Paddenhoek 20, B-9830 St.-Martens Latem (BE). **LISSENS, Ann** [BE/BE]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). **BOGAERT, Thierry** [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).

(74) Agent: **BAYLISS, Geoffrey, Cyril**; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/48183 A2

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

The present invention is concerned with ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that the susceptibility of nematode worms such as *C. elegans* to double stranded RNA inhibition is affected by changes in the genetic background of the worms.

It has recently been described in Nature Vol 391, pp.806-811, February 98, that introducing double stranded RNA into a cell results in potent and specific interference with expression of endogenous genes in the cell, which interference is substantially more effective than providing either RNA strand individually as proposed in antisense technology. This specific reduction of the activity of the gene was also found to occur in the nematode worm Caenorhabditis elegans (*C. elegans*) when the RNA was introduced into the genome or body cavity of the worm.

The present inventors have utilized the double stranded RNA inhibition technique and applied it further to devise novel and inventive methods of (i) assigning functions to genes or DNA fragments which have been sequenced in various projects, such as, for example, the human genome project and which have yet to be accorded a particular function, and (ii) identifying DNA responsible for conferring a particular phenotype. Such methods are described in the applicant's co-pending application number WO 00/01846. Processes for introducing RNA into a living cell, either *in vivo* or *ex vivo*, in order to inhibit expression of a target gene in that cell are

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*. One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence, corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.

Caenorhabditis elegans is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes, preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type genetic background which confers greater sensitivity to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing susceptibility of the nematode to RNAi may, for example, affect the stability of dsRNA or the kinetics of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding proteins involved in RNA synthesis, RNA degradation or the regulation of these processes.

In one preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known *per se* in the art.

In a second preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

C. elegans feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called pharyngeal pumping. Once the food particles have been internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport of molecules through the gut wall.

C. elegans mutants which exhibit increased uptake of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the *C.*

elegans Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "*C. elegans*: Modern biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium under accession number LMBP 5334CB. The phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

For the avoidance of doubt, where particular characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans,* wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, Caenorhabditis elegans: Modern biological analysis of an organism, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode Caenorhabditis elegans, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans* II, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.

Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that variations in the food organism can result in enhanced *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can be any modification which results in increased expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In a preferred embodiment, the food organism is an RNAse III minus *E. coli* strain, or any other RNAse negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

Several different arrangements of promoters may be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical. Transcription from the opposable promoters produces two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans unc-22* gene. In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire in Methods in Cell Biology, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode, resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as used herein is to be interpreted accordingly. Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at WWW.ncbi.nlm.nih.gov.

The invention will be further understood with reference to the following non-limiting Examples, together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans unc-22* gene cloned in pGN1).

Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGX104

Example 1

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

Introduction

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

For this experiment the following *E. coli* strains were used:

1. MC1061: F-*araD139 Δ(ara-leu)7696 galE15 galK16 Δ(lac)X74 rpsl (Str^r) hsdR2 (r_k^- m_k^+) mcrA mcrB1*
   - regular host for various plasmids,
   - Wertman et al., (1986) Gene 49:253-262,
   - Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.

2. B21(DE3): F- *ompT(lon) hsdS$_B$* (r_B^-,m_B^-; an *E. coli* B strain) with DE3, a λ prophage carrying the T7 RNA polymerase gene.
   - regular host for IPTG inducible T7 polymerase expression,
   - Studier et al. (1990) Meth. Enzymol. 185:60-89

3. HT115 (DE3): F- *mcrA mcrb* IN(rrnD-rrnE) 1 λ- *rnc14::tr10* (DE3 lysogen: lacUV5 promoter-T7polymerase)
   - host for IPTG inducible T7 polymerase

expression,
- RNaseIII-,
- Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

For this experiment the following *C. elegans* strains were used:

1. C. elegans N2: regular WT laboratory strain

2. *C. elegans nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death; ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
   - Stanfield et al. (1998) East Coast Worm meeting abstract 171,
   - Anonymous, Worm Breeder's Gazette 1(1):17b Hevelone et al. (1988) Biochem. Genet. 26:447-461
   - Ellis et al., Worm breeder's Gazette 7(2):44
   - Babu, Worm Breeder's gazette 1(2):10
   - Driscoll, (1996) Brain Pathol. 6:411-425
   - Ellis et al., (1991) Genetics 129:79-94

For this experiment the following plasmids were used:

pGN1: A vector encoding for ampicillin resistance, harbouring a multiple cloning site between two convergent T7 promoters.

pGN8: pGN1 containing a genomic fragment of *unc-22*. Decreased unc-22 expression via RNAi results in a "twitching" phenotype in *C. elegans*.

Experimental conditions

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M $CaCl_2$, 9.5 ml 0.1 ml $MgSO_4$, 25 ml 1M KH_2PO_4/K_2HPO_4 buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH_3COONH_4 7.5 M).

The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria lawn, and incubated at 37°C for approximately 4 hours. Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of the seeded nematodes were tested for the twitching phenotype.

Results

Table 1: Percentage of the offspring that show the twitching phenotype

MC1061	**N2**	***nuc-1***
pGN1	0%	0%
pGN1 + IPTG	0%	0%
pGN8	0%	0%
pGN8 + IPTG	0%	0%
BL21(DE3)		
pGN1	0%	0%
pGN1 + IPTG	0%	0%
pGN8	20% (+)	>90% (++)
pGN8 + IPTG	20% (+)	>90% (++±)
HT115(DE3)		
pGN1	0%	0%
pGN1 + IPTG	0%	0%
pGN8	50% (+±)	>90% (++)
pGN8 + IPTG	80% (++)	>90% (+++)

%: percentage twitchers
+: weak twitching
++: twitching
+++: strong twitching

Conclusions

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment. Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the unc-22 fragment cloned in pGN8 is not

expressed as dsRNA.

The experiment with *E. coli* strain BL21(DE3) and nematode strain N2 shows expected results. BL21(DE3) harbouring plasmid pGN1 does not result in any twitching as the pGN1 vector is an empty vector. BL21 (DE3) harbouring PGN8 results in the expression of unc-22 dsRNA. When this dsRNA is fed to the N2 nematode (indirectly by feeding with the bacteria that produce the dsRNA), this results in a twitching phenotype, indicating that the dsRNA is able to pass the gut barrier and is able to perform its interfering activity.

Surprisingly the RNAi effect of the unc-22 dsRNA was even more pronounced in *C. elegans* strain *nuc-1* than in the wild type N2 strain. Although one may expect that the *nuc-1* mutation results in the non-degradation or at least in a slower degradation of DNA, as the NUC-1 protein is known to be involved in DNAse activity, we clearly observe an enhancement of the RNAi induced phenotype in *C. elegans* with a *nuc-1* background. The *nuc-1* mutation has not been cloned yet, but it has been described that the gene is involved in nuclease activity, and more particularly DNAse activity. If the NUC-1 protein is a nuclease, it may also have activity on nuclease activity on dsRNA, which would explain the enhanced RNAi phenotype. The *nuc-1* gene product may be a nuclease, or a regulator of nuclease activity. As the mode of action of RNAi is still not understood, it is also possible that the NUC-1 protein is interfering in the mode of action of RNAi. This would explain why a *nuc-1* mutant is more sensitive to RNAi.

The experiment with the *E.coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the unc-22 dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNAse III minus strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans nuc-1* with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can realised using a nuclease negative *C. elegans* and more particularly with a with the *C. elegans nuc-1* (e1392) strain.

Summary

RNA interference can be achieved in *C. elegans* by feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus stains. In this example the level of dsRNA production varied: HT115(DE3)>BL21(DE3)>MC1061.

RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans nuc-1*.
In this example the sensitivity to RNAi varied:
C. elegans nuc-1 >> C. elegans N2

Example 2

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake (designated herein 'gun' mutants). Strains bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

Experimental conditions:

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100µg/ml) and 5 ml of 100mM stock IPTG) per well
- the dried plates were spotted with 25µl of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype

Results:

Table 2:

20°C/6d	pGN1 HT115DE3	pGN8 BL2DE3	pGN8 HT115DE3	
N2	0	1	1	
nuc-1	0	1-2	3	
bg77	0	1-2	3	
bg78	0	1	1-2	
bg83	0	1	1	
bg84	0	1-2	3	
bg85	0	1	2-3	
bg86	0	1	2-3	
bg87	0	1	1	
bg88	0	1	1	
bg89	0	1	1	

figure legend:

0 = no twitching

1 = no to weak phenotype

2 = clear phenotype

3 = strong phenotype

Conclusions

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1 C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains bg77, bg84, bg85, bg86 show improved sensitivity to RNAi compared to Wild-type.

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

Double mutants were constructed to test the prediction that gun/nuc mutants would even show more enhanced RNAi sensitivity. As an example, the crossing strategy with gun strain bg85 is shown, similar crosses can be conducted with other gun strains, such as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

F1 cross: nuc-1 x gun(bg85)/+ males

F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)
nuc-1 x +/+; nuc-1/0 males (50%)

F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)
+/+; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th plate high staining with BCECF)

F5 retest: gun(bg85); nuc-1 (100% progeny of F4 singled high staining with BCECF)

To select for the gun phenotype, the fluorescence precursor BCECF-AM is used (obtainable from Molecular probes). The precursor BCECF-AM is cleaved by esterases present in the gut of the worm to generate the dye BCECF which is fluorescent at pH values above 6. This allows selection for worms that have a gun phenotype. BCECF-AM is taken up through the pharynx into the gut lumen and is not fluorescent until it has been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

Example 3

Improved RNAi feeding in liquid culture using *nuc-1*(e1393) *C. elegans*.

Introduction

N2 and nuc-1 *C.elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using the nuc-1 strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E.coli* strains were used:

1. HT115 (DE3): F- *mcrA mcrb IN*(rrnD-rrnE) 1 λ- *rnc14::tr10* (DE3 lysogen: lacUV5 promoter -T7 polymerase)
   - host for IPTG inducible T7 polymerase expression
   - RNaseIII⁻
   - Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

For this experiment, following *C. elegans* strains were used:

1. *C. elegans* N2: regular WT laboratory strain

2. *C. elegans nuc-1*(e1393): *C. elegans* strain with a reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
- Stanfield et al. (1998) East Coast Worm meeting abstract 171
- Anonymous, Worm Breeder's Gazette 1(1):17b
- Hevelone et al. (1988) Biochem. Genet. 26:447-461
- Ellis et al., Worm breeder's Gazette 7(2):44
- Babu, Worm Breeder's gazette 1(2):10
- Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

For this experiment, the following plasmids that all give lethal phenotypes in *C. elegans* via RNAi were used:

pGX22: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid C04H5.6 corresponding to a member of the RNA helicase family.

pGX52: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid K11D9.2b corresponding to sarco/endoplasmic $Ca2^{+}$ ATPase also known as SERCA.

pGZ18: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid T25G3.2 corresponding to a chitin like synthase gene.

pGX104: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid Y57G11C.15 corresponding to sec-61, a transport protein.

Experimental conditions

- 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.

- 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.

- 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).

- the plates were incubated at 25°C for 5 days to allow offspring to be formed.

- the plates were visually checked and the following phenotypes could be scored per individual well:

no effect: L1's developed to adults and gave normal offspring.

no F1 offspring: L1's developed to adults and gave no offspring.

acute lethal: original L1 did not mature and died.

Results

The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

a percentage of the total (n=16) on the y-axis for both N2 and *nuc-1* strains.

Conclusions

The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- SERCA: a sarco/endoplasmic Ca^{2+} ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- T25G3.2: a chitin like synthase gene. RNAi of this gene causes dead eggs.
- sec-61: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the nuc-1 *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and Sec-61 the difference between the N2 wild-type strain and the nuc-1 stain is less pronounced.

Example 4

Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi

A set of primers for each gene was designed on the basis of sequence data available in the publicly accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

1. **C04H5.6**=member of RNA helicase
2. **K11D9.2b**=SERCA
3. **Y57G11C.15**=transport protein sec-61
4. **T25G3.2**=chitin synthase like

The following primer sequences were designed:

1. **C04H5.6F** 5'-TGCTCAGAGAGTTTCTCAACGAACC-3'
   C04H5.6R 5'-CAATGTTAGTTGCTAGGACCACCTG-3'

2. **K11D9.2bF** 5'-CAGCCGATCTCCGTCTTGTG-3'
   K11D9.2bR 5'-CCGAGGGCAAGACAACGAAG-3'

3. **Y57G11C.15F** 5'-ACCGTGGTACTCTTATGGAGCTCG-3'
   Y57G11C.15R 5'-TGCAGTGGATTGGGTCTTCG-3'

4. **T25G3.2F**
   5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'

   T25G3.2R
   5'-GGGGACCACTTTGTACAAGAAAGCTGGGTTGGAGAAGCATTCCGAGAGTTTG-3'

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

1326bp for C04H5.6
1213bp for K11D9.2b

1024bp for Y57G11C.15
1115bp for T25G3.2

The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15 were linked to *Bst*XI adaptors (Invitrogen) and then cloned into the pGN29 vector cut with *Bst*XI. pGN29 contains two T7 promoters and two T7 terminators flanking a cloning site which is adapted for facilitated cloning of PCR fragments, comprising a stuffer DNA flanked by two *Bst*XI sites (see schematic Figure 3). The resulting plasmids were designated pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104 (Y57G11C.15).

The PCR fragment of T25G3.2 was cloned into pGN39 via recombination sites based on the GATEWAY™ cloning system (Life Technologies, Inc). pGN39 contains two T7 promoters and two T7 terminators flanking a cloning site which facilitates "High Throughput" cloning based on homologous recombination rather than restriction enzyme digestion and ligation. As shown schematically in Figure 4, the cloning site comprises *att*R1 and *att*R2 recombination sites from bacteriophage lambda flanking a gene which is lethal to *E. coli*, in this case the *ccd*B gene. This cloning site is derived from the Gateway™ cloning system commercially available from Life Technologies, Inc. The Gateway™ cloning system has been extensively described by Hartley *et al.* in WO 96/40724 (PCT/US96/10082).

Example 5

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

The screen was performed in *unc-31*(*e928*) mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethylester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

Mutagenesis

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x)
9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

Table 3: Isolation of mutations for increased staining with BCECF-AM

Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
(counted)	(estimated)	(calculated)	(estimated)	(counted)
2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

1. backcrossing *unc-31; gun* --> *unc-31; gun*
- *unc-31; gun* x WT males
- singled 2x5 WT hermaphrodites F1s (*unc-31/+;gun/+*)
- singled 50 WT hermaphrodites F2s (1/4 homozygous)
- select strains segregating 1/4 unc
- stain unc strains with BCECF-AM
- from positive strains pick unc homozygous
- retest 100 % unc strains with BCECF-AM
- kept 1 strain (backcrossed)

2. *unc-31* background was crossed out-->+; *gun*
- *unc-31; gun* x WT males
- singled 2x5 WT hermaphrodites F1s (*unc-31/+;gun/+*)
- singled 50 WT hermaphrodites F2s (1/4 homozygous)
- select strains which did not segregate unc F3s anymore
- stain non unc strains with BCECF-AM
- 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)

3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
- *gun* x WT males
- WT hermaphrodites x F1 males (*gun/+*)
- singled 10 WT hermaphrodites F2s (½ heterozygous)
- singled 50 WT hermaphrodites F3s (1/8 homozygous)

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1*(X) mutant--> *gun; nuc-1*
- *gun* x WT males
- *nuc-1* x *gun/+* males
- *nuc-1* x *gun/+; nuc-1/0* or *+/+; nuc-1/0* males
- singled 10 WT hermaphrodite progeny (*nuc-1* homozygous, ½ heterozygous *gun*)
- singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)
- stain strains with BCECF-AM
- retested positives with BCECF-AM and finally 1 was selected and kept

Table 6: Strains derived from gun mutations

gun	*unc-31; gun*		*unc-31; gun*		*+; gun*			*gun; nuc-1*
	original isolate		backcrossed (1x)		outcrossed (1x)		3x b.c.	from 3x b.c.
allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number	strain number
bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777
bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675	–
bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676	–
bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774
bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775
bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776
bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679	–
bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680	–
bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671	–

SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

SEQ ID NO: 4 complete sequence of pGN39

SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

SEQ ID NO: 14 primer Y57G11C.15R

SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.

2. A method as claimed in claim 1 wherein the nematode is a microscopic nematode.

3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.

4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.

5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic background.

6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild type.

7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.

8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type.

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

18. A method as claimed in claim 26 wherein the two promoters are identical.

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the double-stranded RNA compared to a food organism which does not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNAse III minus strain or any other RNAse negative strain.

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28 to 31 wherein the nematode has a mutant genetic background.

33. A method as claimed in claim 32 wherein the nematode is mutant *C. elegans* strain bg85.

34. A method as claimed in any one of claims 28 to 33 wherein the DNA capable of producing a double-stranded RNA structure is a vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

35. A method as claimed in claim 34 wherein the vector comprises two promoters flanking the DNA sequence.

36. A method as claimed in claim 35 wherein the two promoters are identical.

37. A method as claimed in claim 34 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

38. A method as claimed in any one of claims 34 to 37 wherein the nematode is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

39. A method as claimed in any one of claims 34

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

FIG. 1.


PHAGE F1
LAC OPERON
T7 Promoter
T7 Promoter (complement)
SP6 P
pGN1
3216 bp
APr
LAC OPERON

FIG. 2.


T7P
BamHI
LAC OPERON
PHAGE F1
part of exon 27
exon 26
pGN8
4620 bp
exon 25
part of exon 24
HindIII
SP6P
T7
LAC OPERON
APr

FIG. 3.


PHAGE F1
LAC OPERON
T7 P
T7-terminator
Bst XI (818)
polylinker & stuffer
Bst XI (1174)
T7-terminator
SP6 P
T7
LAC OPERON
APr
pGN29
3774 bp

FIG. 4.


T7 P
LAC OPERON
T7-terminator
PHAGE F1
BstXI (135)
attR1
Cm+
pGN39
5200 bp
ccdA
APr
ccdB
BstXI (1632)
attR2
BstXI (1917)
T7-terminator
SP6 P
T7
LAC OPERON

FIG. 5.


BstXI (4753)
T7-terminator
T7 P
SENSE PRM
LAC OPERON
PHAGE F1
LONG
C04H5.6 (helicase)
pGX22
4756 bp
ANTISENSE PRM
BstXI (1335)
T7-terminator
SP6 P
T7
LAC OPERON
APr

FIG. 6.


PHAGE F1
LAC OPERON
M13(-21)
T7 P
T7-terminator
BstXI (818)
APr
pGX52
4643 bp
k11D9.2b fragment
BstXI (2043)
T7-terminator
SP6 P
T7
M13rvPE
LAC OPERON

FIG. 7.


PHAGE F1
LAC OPERON
M13(-21)
T7 P
T7-terminator
BstXI (818)
AP
pGX104
4454 bp
Y57G11c.15 long
BstXI (1854)
T7-terminator
SP6 P
T7
M13rvPE
LAC OPERON

FIG. 8.


attB2
attR2
BstXI (41)
ANTISENSE PRM
o-GN106
LONG
T7-terminator
SP6 P
T7
M13RV
LAC OPERON
LONG
SENSE PRM
attB1
attR1
BstXI (3459)
o-GN105
T7-terminator
T7 P
M13FW(-20)
LAC OPERON
PHAGE F1
pGZ18
4701 bp
APr

FIG. 9.


Helicase, pGX22
100%
80%
60%
40%
20%
0%
12.5
87.5
100
N2
nuc-1
RNAi liquid screen
no effect
no F1 offspring

FIG. 10.


SERCA, pGX52
100%
80%
60%
40%
20%
0%
75
18.75
6.25
37.5
6.25
56.2
N2
nuc-1
RNAi liquid screen
no effect
no F1 offspring
acute lethal

FIG. 11.


Chitine synthase, pGZ18
100%
80%
60%
40%
20%
0%
75
25
100
N2
nuc-1
RNAi liquid screen
no effect
dead eggs

FIG. 12.


Sec-61, pGX104
100%
80%
60%
40%
20%
0%
6 25
93 75
100
N2
nuc-1
RNAi liquid screen
no F1 offspring
acute lethal

SEQUENCE LISTING

<110> DEVGEN NV

<120> IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

<130> SCB/53711/001

<140>
<141>

<160> 14

<170> PatentIn Ver. 2.0

<210> 1
<211> 3216
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGN1

<400> 1
gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tattttgtta aaattcgcgt taaatatttg ttaaatcagc 120
tcatttttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
cccaaatcaa gtttttgcg gtcgaggtgc cgtaaagctc taaatcggaa ccctaaaggg 360
agcccccgat ttagagcttg acggggaaag ccggcgaacg tggcgagaaa ggaagggaag 420
aaagcgaaag gagcgggcgc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt ccattcgcca ttcaggctgc 540
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gttttcccag tcacgacgtt 660
gtaaaacgac ggccagtgaa ttgtaatacg actcactata gggcgaattc gagctcggta 720
cccggggatc ctctagagtc gaaagcttct cgccctatag tgagtcgtat tacagcttga 780
gtattctata gtgtcaccta aatagcttgg cgtaatcatg gtcatagctg tttcctgtgt 840
gaaattgtta tccgctcaca attccacaca acatacgagc cggaagcata aagtgtaaag 900
cctggggtgc ctaatgagtg agctaactca cattaattgc gttgcgctca ctgcccgctt 960
tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc gcggggagag 1020
gcggtttgcg tattgggcgc tcttccgctt cctcgctcac tgactcgctg cgctcggtcg 1080
ttcggctgcg gcgagcggta tcagctcact caaaggcggt aatacggtta tccacagaat 1140
caggggataa cgcaggaaag aacatgtgag caaaaggcca gcaaaaggcc aggaaccgta 1200
aaaaggccgc gttgctggcg tttttcgata ggctccgccc ccctgacgag catcacaaaa 1260
atcgacgctc aagtcagagg tggcgaaacc cgacaggact ataaagatac caggcgtttc 1320
cccctggaag ctccctcgtg cgctctcctg ttccgaccct gccgcttacc ggatacctgt 1380
ccgcctttct cccttcggga agcgtggcgc tttctcatag ctcacgctgt aggtatctca 1440
gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca cgaaccccc gttcagcccg 1500
accgctgcgc cttatccggt aactatcgtc ttgagtccaa cccggtaaga cacgacttat 1560
cgccactggc agcagccact ggtaacagga ttagcagagc gaggtatgta ggcggtgcta 1620
cagagttctt gaagtggtgg cctaactacg gctacactag aaggacagta tttggtatct 1680
gcgctctgct gaagccagtt accttcggaa aaagagttgg tagctcttga tccggcaaac 1740
aaaccaccgc tggtagcggt ggtttttttg tttgcaagca gcagattacg cgcagaaaaa 1800
aaggatctca agaagatcct ttgatctttt ctacggggtc tgacgctcag tggaacgaaa 1860
actcacgtta agggattttg gtcatgagat tatcaaaaag gatcttcacc tagatccttt 1920
taaattaaaa atgaagtttt aaatcaatct aaagtatata tgagtaaact tggtctgaca 1980

gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctattt cgttcatcca 2040
tagttgcctg actccccgtc gtgtagataa ctacgatacg ggagggctta ccatctggcc 2100
ccagtgctgc aatgataccg cgagacccac gctcaccggc tccagattta tcagcaataa 2160
accagccagc cggaagggcc gagcgcagaa gtggtcctgc aactttatcc gcctccatcc 2220
agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca 2280
acgttgttgg cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt atggcttcat 2340
tcagctccgg ttcccaacga tcaaggcgag ttacatgatc ccccatgttg tgcaaaaaag 2400
cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca gtgttatcac 2460
tcatggttat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt 2520
ctgtgactgg tgagtactca accaagtcat tctgagaata ccgcgcccgg cgaccgagtt 2580
gctcttgccc ggcgtcaata cgggataata gtgtatgaca tagcagaact ttaaaagtgc 2640
tcatcattgg aaaacgttct tcggggcgaa aactctcaag gatcttaccg ctgttgagat 2700
ccagttcgat gtaacccact cgtgcaccca actgatcttc agcatctttt actttcacca 2760
gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga ataagggcga 2820
cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg 2880
gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg 2940
ttccgcgcac atttccccga aaagtgccac ctgacgtcta agaaaccatt attatcatga 3000
cattaaccta taaaaatagg cgtatcacga ggccctttcg tctcgcgcgt ttcggtgatg 3060
acggtgaaaa cctctgacac atgcagctcc cggagacggt cacagcttgt ctgtaagcgg 3120
atgccgggag cagacaagcc cgtcagggcg cgtcagcggg tgttggcggg tgtcggggct 3180
ggcttaacta tgcggcatca gagcagattg tactga 3216

<210> 2
<211> 4620
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGN8

<400> 2
gatccgaatc tccatgtctg ttaacagcct tgacacggaa tttatattca tgcccttgag 60
tcaaatcgtc aacgtggaag ttggtatcct tgctctctcc gcaagcagtc catctgccag 120
tggcagcatc ttgcttttca atgacatagt gactgatttc agctcctcca tcatcttctg 180
gttccttcca tgcaagatca catccatcct tgacaatatt agtgacatcg agaggtccac 240
gtgggcttga tggatgatca agaacagtaa ccttcacttc agcagtgtca gttccattct 300
cgttctctgc cttgatgata taggttcctg tatccgaacg caaagctctc ttcacatgga 360
atttagtctt gccgtcttca ttgttcaact tcatacgatc atcagattcg actggtgttc 420
cttcgaaagt ccaagtaatt gttggagttg gttcaccact gactggaatg ttcaatgaga 480
agtcttgtcc agccttgacc ttgatttctt gaatcgagtt acgatcgatg actggtggaa 540
ctataattta attcaatgat tattagtaat tgatttagac tcttaccatt tctagccttt 600
gcaacagctg atgctgaatc agatggatct cccaatcctg ccttgttctt ggcacggatt 660
ctgaattcgt actttgatcc ttccttgaga tttccaacag tagcattcgt ttgtccagct 720
ggaacatgag caacgtcatt ccagaatggc gagaactcgt ccttcatctc aacaacgtat 780
tcctcgattg gagcaccacc gtcgtttgct ggtggcttcc attcaaggtc aacatgatcc 840
ttatcccaat cagtaatttc aggagcattt gtctttcctg gcttgtcaaa tggatctttg 900
gcaagtgtgg ttccgaaggt ctccaatgga tcggactctc cttcagcatt gacggcagcg 960
acacggaact gaaaatcaaa atgttgtagg caattgagtt caagattaaa aaattctcac 1020
tttatattca tgtccaggaa taagaccgtc aacaacagct gtagtcttat ctccagcgac 1080
ctttgcagct ggaacccatc ttccacttgc agtatcgtac ttttcgatca catagttttc 1140
aattggaata cctccatcat catctggtgc acgccaattc aaagtgacat gatcaccatg 1200
aacatcggaa acatctaatg gaccatttgg agaagttggc ttgtctgaaa atttaaaata 1260
taaccaaatt aattgaagaa aactaatgct caccaataac attgatctta acagttgctt 1320
catcttctcc atttgcattg acagctttga tagtgaaagt tccactgtct ccacgttcca 1380
tttgcttcac aaccagcttt gattggtatt ctgggttatc aagcttctcg ccctatagtg 1440
agtcgtatta cagcttgagt attctatagt gtcacctaaa tagcttggcg taatcatggt 1500
catagctgtt tcctgtgtga aattgttatc cgctcacaat tccacacaac atacgagccg 1560
gaagcataaa gtgtaaagcc tggggtgcct aatgagtgag ctaactcaca ttaattgcgt 1620

tgcgctcact gcccgctttc cagtcgggaa acctgtcgtg ccagctgcat taatgaatcg 1680
gccaacgcgc ggggagaggc ggtttgcgta ttgggcgctc ttccgcttcc tcgctcactg 1740
actcgctgcg ctcggtcgtt cggctgcggc gagcggtatc agctcactca aaggcggtaa 1800
tacggttatc cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 1860
aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt tttcgatagg ctccgccccc 1920
ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat 1980
aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc 2040
cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcatagct 2100
cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg 2160
aacccccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 2220
cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 2280
ggtatgtagg cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa 2340
ggacagtatt tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta 2400
gctcttgatc cggcaaacaa accaccgctg gtagcggtgg ttttttgtt tgcaagcagc 2460
agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg 2520
acgctcagtg gaacgaaaac tcacgttaag ggattttggt catgagatta tcaaaaagga 2580
tcttcaccta gatcctttta aattaaaaat gaagttttaa atcaatctaa agtatatatg 2640
agtaaacttg gtctgacagt taccaatgct taatcagtga ggcacctatc tcagcgatct 2700
gtctatttcg ttcatccata gttgcctgac tccccgtcgt gtagataact acgatacggg 2760
agggcttacc atctggcccc agtgctgcaa tgataccgcg agacccacgc tcaccggctc 2820
cagatttatc agcaataaac cagccagccg gaagggccga gcgcagaagt ggtcctgcaa 2880
ctttatccgc ctccatccag tctattaatt gttgccggga agctagagta agtagttcgc 2940
cagttaatag tttgcgcaac gttgttggca ttgctacagg catcgtggtg tcacgctcgt 3000
cgtttggtat ggcttcattc agctccggtt cccaacgatc aaggcgagtt acatgatccc 3060
ccatgttgtg caaaaaagcg gttagctcct tcggtcctcc gatcgttgtc agaagtaagt 3120
tggccgcagt gttatcactc atggttatgg cagcactgca taattctctt actgtcatgc 3180
catccgtaag atgcttttct gtgactggtg agtactcaac caagtcattc tgagaatacc 3240
gcgcccggcg accgagttgc tcttgcccgg cgtcaatacg ggataatagt gtatgacata 3300
gcagaacttt aaaagtgctc atcattggaa aacgttcttc ggggcgaaaa ctctcaagga 3360
tcttaccgct gttgagatcc agttcgatgt aacccactcg tgcacccaac tgatcttcag 3420
catcttttac tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa 3480
aaaagggaat aagggcgaca cggaaatgtt gaatactcat actcttcctt tttcaatatt 3540
attgaagcat ttatcagggt tattgtctca tgagcggata catatttgaa tgtatttaga 3600
aaaataaaca aatagggggtt ccgcgcacat ttccccgaaa agtgccacct gacgtctaag 3660
aaaccattat tatcatgaca ttaacctata aaaataggcg tatcacgagg ccctttcgtc 3720
tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggtca 3780
cagcttgtct gtaagcggat gccgggagca gacaagcccg tcagggcgcg tcagcgggtg 3840
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 3900
accatatgcg gtgtgaaata ccgcacagat gcgtaaggag aaaataccgc atcaggcgaa 3960
attgtaaacg ttaatatttt gttaaaattc gcgttaaata tttgttaaat cagctcattt 4020
tttaaccaat aggccgaaat cggcaaaatc ccttataaat caaaagaata gaccgagata 4080
gggttgagtg ttgttccagt ttggaacaag agtccactat taaagaacgt ggactccaac 4140
gtcaaagggc gaaaaaccgt ctatcagggc gatggcccac tacgtgaacc atcacccaaa 4200
tcaagttttt tgcggtcgag gtgccgtaaa gctctaaatc ggaaccctaa agggagcccc 4260
cgatttagag cttgacgggg aaagccggcg aacgtggcga gaaaggaagg gaagaaagcg 4320
aaaggagcgg gcgctagggc gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca 4380
cccgccgcgc ttaatgcgcc gctacagggc gcgtccattc gccattcagg ctgcgcaact 4440
gttgggaagg gcgatcggtg cgggcctctt cgctattacg ccagctggcg aaaggggat 4500
gtgctgcaag gcgattaagt tgggtaacgc cagggttttc ccagtcacga cgttgtaaaa 4560
cgacggccag tgaattgtaa tacgactcac tatagggcga attcgagctc ggtacccggg 4620

<210> 3
<211> 4756
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGX22

<400> 3
tgctcagaga gtttctcaac gaacccgatt tggctagtta taggtaattt ttagaacatt 60
tacaaaaaca gcaaaaaaac caaacattca ggatttttgt ttttaattaa gaaaaaaatc 120
gatcgctctt aaatttttaat caatacttcg aataaaccca aaaaaaaacg aaaaaaaatc 180
ctgtttccag tgtaatgatg attgacgagg ctcacgaacg tactctacac acggatattc 240
tattcggttt agtcaaagat attgcaagat tccgaaagga tttgaagctt ctcatctctt 300
ctgcaacact tgacgctgaa aagttctcca gtttcttcga cgacgctccg attttccgaa 360
ttccgggacg cagattcccg gtggacattt actatacaca ggctcccgaa gcggactacg 420
tcgacgcggc tatcgtcaca attatgcaga ttcacttgac ccagccactt cccggcgata 480
ttttggtatt tctgactggt caggaagaaa tcgaaactgt acaggaagca cttatggaac 540
ggtcgaaagc actgggatcg aagattaagg agcttattcc gctgccggtt tatgcgaatt 600
tgcccagtga tttgcaggcg aagattttcg agccaacgcc gaaagatgcg agaaaggtag 660
atttttctta caaatttttt ccaaaaaaaa atccgagaaa aatctacaaa atttcaggca 720
aaaactgttt cattttattc ctaactagtt ttttagcaaa cgtttagatt taacaaaact 780
gaacaaattt gaagttttcc aatttaaaaa ataaatgttt cggaaagttt attgaaaaat 840
ctgaaattgc tatcctctcg tatctgcaaa aaaaacactt taaaaaatgc tctgttcttt 900
gaaaatttct aaactgaaaa atttgaaatt tctgaaaatt gtgataattt tataaaattt 960
tatagaaaat gtaagcattc cagaaaaata tcaaaaattt cgagaaaatt ctgaaaaaat 1020
ccagaaatat taacagaaaa aaaatctttt gaaacatctg aaaattaaaa taaattgaat 1080
ttacattttt ttttttggga tttccttaaa atcactatga atttaccact aaatttttg 1140
caaaaaatta ttttttttaat ttcaaagaaa aagcaaagaa ttttaaaata tcaaaaagtc 1200
caaatttggt tcggtgaatt tttaaaataa cattttcaag ataattttaa gttaatcaaa 1260
acattccacg catttctagt ttcccaaatt tctctaaatt tcaggtggtc ctagcaacta 1320
acattgccag cacaatggat ctcgagggat cttccatacc taccagttct gcgcctgcag 1380
gtcgcggccg cgactctcta gacgcgtaag cttactagca taacccctg gggcctctaa 1440
acgggtcttg aggggttttt tgagcttctc gccctatagt gagtcgtatt acagcttgag 1500
tattctatag tgtcacctaa atagcttggc gtaatcatgg tcatagctgt ttcctgtgtg 1560
aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc 1620
ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt 1680
ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg 1740
cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt 1800
tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc 1860
aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa 1920
aaaggccgcg ttgctggcgt ttttcgatag gctccgcccc cctgacgagc atcacaaaaa 1980
tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc 2040
ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc 2100
cgcctttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag 2160
ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaacccccg ttcagcccga 2220
ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc 2280
gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac 2340
agagttcttg aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg 2400
cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca 2460
aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa 2520
aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa 2580
ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt 2640
aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt ggtctgacag 2700
ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat 2760
agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc 2820
cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa 2880
ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca 2940
gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa 3000
cgttgttggc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt 3060
cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc 3120
ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact 3180
catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc 3240
tgtgactggt gagtactcaa ccaagtcatt ctgagaatac cgcgcccggc gaccgagttg 3300
ctcttgcccg gcgtcaatac gggataatag tgtatgacat agcagaactt taaaagtgct 3360

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc 3420
cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag 3480
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac 3540
acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca tttatcaggg 3600
ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt 3660
tccgcgcaca tttccccgaa aagtgccacc tgacgtctaa gaaaccatta ttatcatgac 3720
attaacctat aaaaataggc gtatcacgag gccctttcgt ctcgcgcgtt tcggtgatga 3780
cggtgaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgtc tgtaagcgga 3840
tgccgggagc agacaagccc gtcagggcgc gtcagcgggt gttggcgggt gtcggggctg 3900
gcttaactat gcggcatcag agcagattgt actgagagtg caccatatgc ggtgtgaaat 3960
accgcacaga tgcgtaagga gaaaataccg catcaggcga attgtaaac gttaatattt 4020
tgttaaaatt cgcgttaaat atttgttaaa tcagctcatt ttttaaccaa taggccgaaa 4080
tcggcaaaat cccttataaa tcaaaagaat agaccgagat agggttgagt gttgttccag 4140
tttggaacaa gagtccacta ttaaagaacg tggactccaa cgtcaaaggg cgaaaaaccg 4200
tctatcaggg cgatggccca ctacgtgaac catcacccaa atcaagtttt ttgcggtcga 4260
ggtgccgtaa agctctaaat cggaacccta aagggagccc ccgatttaga gcttgacggg 4320
gaaagccggc gaacgtggcg agaaaggaag ggaagaaagc gaaaggagcg ggcgctaggg 4380
cgctggcaag tgtagcggtc acgctgcgcg taaccaccac acccgccgcg cttaatgcgc 4440
cgctacaggg cgcgtccatt cgccattcag gctgcgcaac tgttgggaag ggcgatcggt 4500
gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgcaa ggcgattaag 4560
ttgggtaacg ccagggtttt cccagtcacg acgttgtaaa acgacggcca gtgaattgta 4620
atacgactca ctatagggcg aattcaaaaa acccctcaag acccgtttag aggccccaag 4680
gggttatgct agtgaattct gcagggtacc cggggatcct ctagagatcc ctcgacctcg 4740
agatccattg tgctgg 4756

<210> 4
<211> 4643
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGX52

<400> 4
gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tattttgtta aaattcgcgt taaatatttg ttaaatcagc 120
tcatttttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
cccaaatcaa gtttttgcg gtcgaggtgc cgtaaagctc taaatcggaa ccctaaaggg 360
agcccccgat ttagagcttg acggggaaag ccggcgaacg tggcgagaaa ggaagggaag 420
aaagcgaaag gagcgggcgc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt ccattcgcca ttcaggctgc 540
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gttttcccag tcacgacgtt 660
gtaaaacgac ggccagtgaa ttgtaatacg actcactata gggcgaattc aaaaaacccc 720
tcaagacccg tttagaggcc ccaaggggtt atgctagtga attctgcagg gtacccgggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gcagccgatc tccgtcttgt 840
gaagatctac tccaccacca tccgtatcga tcagtccatc ctcaccggag aatctgtgtc 900
tgttatcaag cacaccgact ctgtgccaga tccacgcgct gttaaccagg acaagaagaa 960
ttgtctgttc tcgggaacca atgtcgcatc tggaaaggct cgtggaatcg tcttcggaac 1020
cggattgacc actgaaatcg gaaagatccg taccgaaatg gctgagaccg agaatgagaa 1080
gacaccactt caacagaagt tggacgaatt cggagagcaa ctttccaagg ttatctctgt 1140
tatttgcgtt gctgtttggg ctatcaacat tggacatttc aacgatccag ctcacggtgg 1200
atcatgggtt aagggagcaa tctactactt caaaatcgcc gttgctcttg ccgtcgctgc 1260
tattccagaa ggacttccag ctgtcatcac cacgtgcctt gccctcggaa ctcgccgtat 1320
ggccaagaag aacgctattg taagatccct tccatccgtc gaaactcttg gatgcacatc 1380
tgttatctgc tctgacaaga ctggaactct caccaccaac cagatgtctg tgtcaaagat 1440

gttcatcgct ggacaagctt ctggagacaa catcaacttc accgagttcg ccatctccgg 1500
atccacctac gagccagtcg gaaaggtttc caccaatgga cgtgaaatca acccagctgc 1560
tggagaattc gaatcactca ccgagttggc catgatctgc gctatgtgca atgattcatc 1620
tgttgattac aatgagacca agaagatcta cgagaaagtc ggagaagcca ctgaaactgc 1680
tcttatcgtt cttgctgaga agatgaatgt tttcggaacc tcgaaagccg gactttcacc 1740
aaaggagctc ggaggagttt gcaaccgtgt catccaacaa aaatggaaga aggagttcac 1800
actcgagttc tcccgtgatc gtaaatccat gtccgcctac tgcttcccag cttccggagg 1860
atctggagcc aagatgttcg tgaagggagc cccagaagga gttctcggaa gatgcaccca 1920
cgtcagagtt aacggacaaa aggttccact cacctctgcc atgactcaga agattgttga 1980
ccaatgcgtg caatacggaa ccggaagaga taccccttcgt tgtcttgccc tcggccagca 2040
caatggatct cgagggatct tccataccta ccagttctgc gcctgcaggt cgcggccgcg 2100
actctctaga cgcgtaagct tactagcata acccccttggg gcctctaaac gggtcttgag 2160
gggttttttg agcttctcgc cctatagtga gtcgtattac agcttgagta ttctatagtg 2220
tcacctaaat agcttggcgt aatcatggtc atagctgttt cctgtgtgaa attgttatcc 2280
gctcacaatt ccacacaaca tacgagccgg aagcataaag tgtaaagcct ggggtgccta 2340
atgagtgagc taactcacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa 2400
cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat 2460
tgggcgctct tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg 2520
agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc 2580
aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt 2640
gctggcgttt ttcgataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag 2700
tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc 2760
cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc 2820
ttcgggaagc gtggcgcttt ctcatagctc acgctgtagg tatctcagtt cggtgtaggt 2880
cgttcgctcc aagctgggct gtgtgcacga acccccccgtt cagcccgacc gctgcgcctt 2940
atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc 3000
agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa 3060
gtggtggcct aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa 3120
gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg 3180
tagcggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga 3240
agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg 3300
gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg 3360
aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt 3420
aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag ttgcctgact 3480
ccccgtcgtg tagataacta cgatacggga gggcttacca tctggcccca gtgctgcaat 3540
gataccgcga gacccacgct caccggctcc agatttatca gcaataaacc agccagccgg 3600
aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt ctattaattg 3660
ttgccgggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcaacg ttgttggcat 3720
tgctacaggc atcgtggtgt cacgctcgtc gtttggtatg gcttcattca gctccggttc 3780
ccaacgatca aggcgagtta catgatcccc catgttgtgc aaaaaagcgg ttagctcctt 3840
cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg ttatcactca tggttatggc 3900
agcactgcat aattctctta ctgtcatgcc atccgtaaga tgcttttctg tgactggtga 3960
gtactcaacc aagtcattct gagaataccg cgcccggcga ccgagttgct cttgcccggc 4020
gtcaatacgg gataatagtg tatgacatag cagaacttta aaagtgctca tcattggaaa 4080
acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca gttcgatgta 4140
acccactcgt gcacccaact gatcttcagc atcttttact ttcaccagcg tttctgggtg 4200
agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac ggaaatgttg 4260
aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt attgtctcat 4320
gagcggatac atatttgaat gtatttagaa aaataaacaa atagggggttc cgcgcacatt 4380
tccccgaaaa gtgccacctg acgtctaaga aaccattatt atcatgacat taacctataa 4440
aaataggcgt atcacgaggc cctttcgtct cgcgcgtttc ggtgatgacg gtgaaaacct 4500
ctgacacatg cagctcccgg agacggtcac agcttgtctg taagcggatg ccgggagcag 4560
acaagcccgt cagggcgcgt cagcgggtgt tggcgggtgt cggggctggc ttaactatgc 4620
ggcatcagag cagattgtac tga 4643

<210> 5
<211> 4454
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGX104

<400> 5
gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tattttgtta aaattcgcgt taaatatttg ttaaatcagc 120
tcatttttta accaataggc cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggt tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
cccaaatcaa gtttttgcg gtcgaggtgc cgtaaagctc taaatcggaa ccctaaaggg 360
agcccccgat ttagagcttg acggggaaag ccggcgaacg tggcgagaaa ggaagggaag 420
aaagcgaaag gagcgggcgc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacacccg ccgcgcttaa tgcgccgcta cagggcgcgt ccattcgcca ttcaggctgc 540
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttggg taacgccagg gttttcccag tcacgacgtt 660
gtaaaacgac ggccagtgaa ttgtaatacg actcactata gggcgaattc aaaaaacccc 720
tcaagacccg tttagaggcc ccaaggggtt atgctagtga attctgcagg gtacccgggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gaccgtggta ctcttatgga 840
gctcggaatc tcgccaatcg tcacttctgg acttatcatg caacttctcg ccggagccaa 900
gatcatcgaa gtcggagaca caccaaagga ccgtgctctt ttcaacggag cccagaaatg 960
taagccgaaa agtgtgtgtt ttcaatctct aatttttgaa cttttcagtg ttcggtatgg 1020
tcatcactgt tggacaagct attgtctacg tcatgtccgg actctacgga gagccatcgg 1080
aaatcggagc tggaatctgt ctccttatcg tcgtccaact cgttattgcc ggtctcatcg 1140
tcctccttct cgacgagctt ctccaaaagg gatatggtct cggatccgga atttctctct 1200
tcattgccac caacatctgt gaaaccattg tctggaaggc attctccccg gcaacaatga 1260
acaccggacg tggaaccgag ttcgaaggag ccgtcattgc tcttttccat cttcttgcca 1320
cccgctccga caaggtccgt gcccttcgtg aggctttcta ccgtcaaaac cttccaaact 1380
tgatgaactt gatggctact ttcctcgttt ttgcggtggt tatctacttc caaggattcc 1440
gtgtcgacct cccaatcaag tctgcccgct accgtggaca atacagcagc tacccaatca 1500
agctcttcta cacctccaac attccaatca tccttcaatc tgctctcgtc tccaacctct 1560
acgttatctc tcaggtttgt tgcatctcag tagtaccgtt agatgtttat ctttctctag 1620
agggtcaagt tggccgagaa atttttgag ttcattctca agtctgatgg aaaatgttta 1680
tttttcagat gctcgccgga aagttcggag gaaacttctt catcaacctt ctcggtacct 1740
ggtccgataa caccggatac agaagctacc caactggagg actctgctac tatctttcac 1800
caccagagtc tcttggacac atcttcgaag acccaatcca ctgcaccagc acaatggatc 1860
tcgagggatc ttccatacct accagttctg cgcctgcagg tcgcggccgc gactctctag 1920
acgcgtaagc ttactagcat aacccccttgg ggcctctaaa cgggtcttga ggggtttttt 1980
gagcttctcg ccctatagtg agtcgtatta cagcttgagt attctatagt gtcacctaaa 2040
tagcttggcg taatcatggt catagctgtt tcctgtgtga aattgttatc cgctcacaat 2100
tccacacaac atacgagccg gaagcataaa gtgtaaagcc tggggtgcct aatgagtgag 2160
ctaactcaca ttaattgcgt tgcgctcact gcccgctttc cagtcgggaa acctgtcgtg 2220
ccagctgcat taatgaatcg gccaacgcgc ggggagaggc ggtttgcgta ttgggcgctc 2280
ttccgcttcc tcgctcactg actcgctgcg ctcggtcgtt cggctgcggc gagcggtatc 2340
agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg caggaaagaa 2400
catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt 2460
tttcgatagg ctccgccccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg 2520
gcgaaacccg acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg 2580
ctctcctgtt ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc cttcgggaag 2640
cgtggcgctt tctcatagct cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc 2700
caagctgggc tgtgtgcacg aacccccccgt tcagcccgac cgctgcgcct tatccggtaa 2760
ctatcgtctt gagtccaacc cggtaagaca cgacttatcg ccactggcag cagccactgg 2820
taacaggatt agcagagcga ggtatgtagg cggtgctaca gagttcttga agtggtggcc 2880
taactacggc tacactagaa ggacagtatt tggtatctgc gctctgctga agccagttac 2940
cttcggaaaa agagttggta gctcttgatc cggcaaacaa accaccgctg gtagcggtgg 3000
tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatccttt 3060
gatcttttct acggggtctg acgctcagtg gaacgaaaac tcacgttaag ggattttggt 3120

catgagatta tcaaaaagga tcttcaccta gatcctttta aattaaaaat gaagttttaa 3180
atcaatctaa agtatatatg agtaaacttg gtctgacagt taccaatgct taatcagtga 3240
ggcacctatc tcagcgatct gtctatttcg ttcatccata gttgcctgac tccccgtcgt 3300
gtagataact acgatacggg agggcttacc atctggcccc agtgctgcaa tgataccgcg 3360
agacccacgc tcaccggctc cagatttatc agcaataaac cagccagccg gaagggccga 3420
gcgcagaagt ggtcctgcaa ctttatccgc ctccatccag tctattaatt gttgccggga 3480
agctagagta agtagttcgc cagttaatag tttgcgcaac gttgttggca ttgctacagg 3540
catcgtggtg tcacgctcgt cgtttggtat ggcttcattc agctccggtt cccaacgatc 3600
aaggcgagtt acatgatccc ccatgttgtg caaaaaagcg gttagctcct tcggtcctcc 3660
gatcgttgtc agaagtaagt tggccgcagt gttatcactc atggttatgg cagcactgca 3720
taattctctt actgtcatgc catccgtaag atgcttttct gtgactggtg agtactcaac 3780
caagtcattc tgagaatacc gcgcccggcg accgagttgc tcttgcccgg cgtcaatacg 3840
ggataatagt gtatgacata gcagaacttt aaaagtgctc atcattggaa aacgttcttc 3900
ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt aacccactcg 3960
tgcacccaac tgatcttcag catcttttac tttcaccagc gtttctgggt gagcaaaaac 4020
aggaaggcaa aatgccgcaa aaaagggaat aagggcgaca cggaaatgtt gaatactcat 4080
actcttcctt tttcaatatt attgaagcat ttatcagggt tattgtctca tgagcggata 4140
catatttgaa tgtatttaga aaaataaaca aatagggttc ccgcgcacat ttccccgaaa 4200
agtgccacct gacgtctaag aaaccattat tatcatgaca ttaacctata aaaataggcg 4260
tatcacgagg ccctttcgtc tcgcgcgttt cggtgatgac ggtgaaaacc tctgacacat 4320
gcagctcccg gagacggtca cagcttgtct gtaagcggat gccgggagca gacaagcccg 4380
tcagggcgcg tcagcgggtg ttggcgggtg tcggggctgg cttaactatg cggcatcaga 4440
gcagattgta ctga 4454

<210> 6
<211> 4701
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Plasmid pGZ18

<400> 6
acccagcttt cttgtacaaa gtggtgatct ttccagcaca atggatctcg agggatcttc 60
catacctacc agttctgcgc ctgcaggtcg cggccgcgac tctctagacg cgtaagctta 120
ctagcataac cccttggggc ctctaaacgg gtcttgaggg gttttttgag cttctcgccc 180
tatagtgagt cgtattacag cttgagtatt ctatagtgtc acctaaatag cttggcgtaa 240
tcatggtcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc acacaacata 300
cgagccggaa gcataaagtg taaagcctgg ggtgcctaat gagtgagcta actcacatta 360
attgcgttgc gctcactgcc cgctttccag tcgggaaacc tgtcgtgcca gctgcattaa 420
tgaatcggcc aacgcgcggg gagaggcggt ttgcgtattg ggcgctcttc cgcttcctcg 480
ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc tcactcaaag 540
gcggtaatac ggttatccac agaatcaggg gataacgcag gaaagaacat gtgagcaaaa 600
ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcgttttt cgataggctc 660
cgcccccctg acgagcatca caaaaatcga cgctcaagtc agaggtggcg aaacccgaca 720
ggactataaa gataccaggc gtttcccccct ggaagctccc tcgtgcgctc tcctgttccg 780
accctgccgc ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct 840
catagctcac gctgtaggta tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt 900
gtgcacgaac cccccgttca gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag 960
tccaacccgg taagacacga cttatcgcca ctggcagcag ccactggtaa caggattagc 1020
agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa ctacggctac 1080
actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga 1140
gttggtagct cttgatccgg caaacaaacc accgctggta gcggtggttt ttttgtttgc 1200
aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg 1260
gggtctgacg ctcagtggaa cgaaaactca cgttaaggga ttttggtcat gagattatca 1320
aaaaggatct tcacctagat ccttttaaat taaaaatgaa gttttaaatc aatctaaagt 1380
atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgaggc acctatctca 1440
gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccgtcgtgta gataactacg 1500

atacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca 1560
ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggt 1620
cctgcaactt tatccgcctc catccagtct attaattgtt gccgggaagc tagagtaagt 1680
agttcgccag ttaatagttt gcgcaacgtt gttggcattg ctacaggcat cgtggtgtca 1740
cgctcgtcgt ttggtatggc ttcattcagc tccggttccc aacgatcaag gcgagttaca 1800
tgatccccca tgttgtgcaa aaaagcggtt agctccttcg gtcctccgat cgttgtcaga 1860
agtaagttgg ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact 1920
gtcatgccat ccgtaagatg cttttctgtg actggtgagt actcaaccaa gtcattctga 1980
gaataccgcg cccggcgacc gagttgctct tgcccggcgt caatacggga taatagtgta 2040
tgacatagca gaactttaaa agtgctcatc attggaaaac gttcttcggg gcgaaaactc 2100
tcaaggatct taccgctgtt gagatccagt tcgatgtaac ccactcgtgc acccaactga 2160
tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaaat 2220
gccgcaaaaa agggaataag ggcgacacgg aaatgttgaa tactcatact cttccttttt 2280
caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt 2340
atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccacctgac 2400
gtctaagaaa ccattattat catgacatta acctataaaa ataggcgtat cacgaggccc 2460
tttcgtctcg cgcgtttcgg tgatgacggt gaaaacctct gacacatgca gctcccggag 2520
acggtcacag cttgtctgta agcggatgcc gggagcagac aagcccgtca gggcgcgtca 2580
gcgggtgttg gcgggtgtcg gggctggctt aactatgcgg catcagagca gattgtactg 2640
agagtgcacc atatgcggtg tgaaataccg cacagatgcg taaggagaaa ataccgcatc 2700
aggcgaaatt gtaaacgtta atattttgtt aaaattcgcg ttaaatattt gttaaatcag 2760
ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac 2820
cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga 2880
ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccatc 2940
acccaaatca agtttttgc ggtcgaggtg ccgtaaagct ctaaatcgga acctaaagg 3000
gagcccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaagggaa 3060
gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgta gcggtcacgc tgcgcgtaac 3120
caccacaccc gccgcgctta atgcgccgct acagggcgcg tccattcgcc attcaggctg 3180
cgcaactgtt gggaagggcg atcggtgcgg gcctcttcgc tattacgcca gctggcgaaa 3240
ggggatgtg ctgcaaggcg attaagttgg gtaacgccag ggttttccca gtcacgacgt 3300
tgtaaaacga cggccagtga attgtaatac gactcactat agggcgaatt caaaaaaccc 3360
ctcaagaccc gtttagaggc cccaaggggt tatgctagtg aattctgcag ggtacccggg 3420
gatcctctag agatccctcg acctcgagat ccattgtgct ggaaagcctt tgcagggctg 3480
gcaagccacg tttggtggtg gcgaccatcc tccaaaatca acaagtttgt acaaaaaagc 3540
aggctatgcc aagtacatgt cgattgcgta cgcgttcgta atgttggctg tgttagtcgc 3600
taccagcagt caaattgttc tcgagagtgc gtttttacat tatcccttca tcctgattac 3660
gacaattttc agctgttctc gctcctacat ctctcttcat tgtcacaatg gtcggaatct 3720
tcttctttgc tgcatgtctt catccaaaag aattcacgaa tattatccat ggtgtcgtat 3780
tcttcctcat gattccatct acatatgtgt tcctcacttt atattcgctc atcaatctca 3840
acgttatcac gtggggaact cgtgaagctg tcgctaaggc aacgggacaa aagacgaaaa 3900
aagcgcctat ggaacaattt atagacagag tgattgatat tgtgaaaaag ggattcagat 3960
taatcagttg tcgggagaag aaggaacatg aagagagacg agagaaaatg gaaaagaaaa 4020
tgcagagaat ggagctagcc ttgagaagta ttgaggttat ctttaacttt agaaatgtga 4080
aattaataat ttattttcag agtggtgccg acgtgaagaa aattctcgat gcaacagagg 4140
agaaggagaa acgtgaagaa gaaactcaaa ctgcagattt tccgattgaa gagaacgtag 4200
agaagactca aaaagagatt cagaaggcaa accgttatgt gtggatgaca agtcatagct 4260
tgaaagtttg tgaacgagga aaactgaaaa gtgcggaaaa ggttttctgg aacgagctca 4320
tcaatgcata tctgaaaccg atcaagacga cgccagctga aatgaaagcc gtcgccgaag 4380
gattggcttc tctacgaaat cagattgctt tcactattct tctcgttaat tctcttcttg 4440
ctcttgccat ctttttgatt cagaaacaca aaaatgtgct cagcatcaag ttctcgccaa 4500
tcagtaagca atattacctt tatggtcaat tcaaaaaatt tgtttttttt ttctagaaaa 4560
cttccgatgg acgaaaatga atgagatgac tggacaatac gaggaaaccg atgaaccatt 4620
aaaaatagat ccacttggaa tgggaattgt tgttttcctt ctaattattc tttttgttca 4680
aactctcgga atgcttctcc a 4701

<210> 7
<211> 25
<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:
Oligonucleotide primer C04H5.6F

<400> 7
tgctcagaga gtttctcaac gaacc 25

<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer C04H5.6R

<400> 8
caatgttagt tgctaggacc acctg 25

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bF

<400> 9
cagccgatct ccgtcttgtg 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer K11D9.2bR

<400> 10
ccgagggcaa gacaacgaag 20

<210> 11
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide
primer Y57G11C.15F

<400> 11
accgtggtac tcttatggag ctcg 24

<210> 12

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide primer Y57G11C.15R

<400> 12
tgcagtggat tgggtcttcg 20

<210> 13
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide primer T25G3.2F

<400> 13
ggggacaagt ttgtacaaaa aagcaggcta tgccaagtac atgtcgattg cg 52

<210> 14
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Oligonucleotide primer T25G3.2R

<400> 14
ggggaccact ttgtacaaga aagctgggtt ggagaagcat tccgagagtt tg 52

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/48183 A3

(51) International Patent Classification[7]: C12N 15/10, 9/22, C07K 14/435, C12N 15/66, 15/70, 1/00

(21) International Application Number: PCT/EP00/13149

(22) International Filing Date:
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9930691.2 24 December 1999 (24.12.1999) GB

(71) Applicant *(for all designated States except US)*: DEVGEN NV [BE/BE]; Technologiepark 9, B-9052 Zwijnaarde (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: PLAETINCK, Geert [BE/BE]; Pontstraat 16, B-9820 Merelbeke (BE). MORTIER, Katherine [BE/BE]; Paddenhoek 20, B-9830 St.-Martens Latem (BE). LISSENS, Ann [BE/BE]; Tiensesteenweg 137, B-3010 Kessel-Lo (BE). BOGAERT, Thierry [BE/BE]; Wolvendreef 26g, B-8500 Kortrijk (BE).

(74) Agent: BAYLISS, Geoffrey, Cyril; Boult Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
6 December 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/48183 A3

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

INTERNATIONAL SEARCH REPORT

rnational Application No
PCT/EP 00/13149

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/10 C12N9/22 C07K14/435 C12N15/66 C12N15/70
C12N1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TIMMONS L ET AL: "Specific interference by ingested dsRNA" NATURE,MACMILLAN JOURNALS LTD. LONDON,GB, vol. 395, no. 6705, 29 October 1998 (1998-10-29), page 854 XP002103601 ISSN: 0028-0836 the whole document ---	1-4, 12-21, 23-25, 28-31, 34-39
A	FIRE A ET AL: "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans" NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, vol. 391, 19 February 1998 (1998-02-19), pages 806-811, XP002095876 ISSN: 0028-0836 cited in the application the whole document --- -/--	1-4

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 July 2001	20/07/2001

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Mateo Rosell, A.M.

1

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP PHILLIP A: "RNAi and double-strand RNA." GENES & DEVELOPMENT, vol. 13, no. 2, 15 January 1999 (1999-01-15), pages 139-141, XP002171268 ISSN: 0890-9369 the whole document	1-4
A	RAY C ET AL: "GUT-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF A CAENORHABDITIS ELEGANS CYSTEINE PROTEASE GENE" MOLECULAR AND BIOCHEMICAL PARASITOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 51, 1992, pages 239-249, XP000572340 ISSN: 0166-6851 abstract	2-4,8
A	RAND J B ET AL: "GENETIC PHARMACOLOGY: INTERACTIONS BETWEEN DRUGS AND GENE PRODUCTS IN CAENORHABDITIS ELEGANS" METHODS IN CELL BIOLOGY,LONDON,GB, vol. 84, 1995, pages 187-204, XP000956211 page 190, paragraph 1 -page 194, paragraph 4	1-4,8
A	AVERY LEON ET AL: "The Caenorhabditis elegans unc-31 gene affects multiple nervous system-controlled functions." GENETICS, vol. 134, no. 2, 1993, pages 455-464, XP001011453 ISSN: 0016-6731 the whole document	2-4,8
A	TAGESSON C ET AL: "INFLUENCE OF SURFACE-ACTIVE FOOD ADDITIVES ON THE INTEGRITY AND PERMEABILITY OF RAT INTESTINAL MUCOSA" FOOD AND CHEMICAL TOXICOLOGY, vol. 22, no. 11, 1984, pages 861-864, XP001009621 ISSN: 0278-6915 the whole document	8

-/--

1

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	LYON CHRISTOPHER J ET AL: "The C. elegans apoptotic nuclease NUC-1 is related in sequence and activity to mammalian DNase II." GENE (AMSTERDAM), vol. 252, no. 1-2, 11 July 2000 (2000-07-11), pages 147-154, XP001009494 ISSN: 0378-1119 abstract; figure 3 page 151, right-hand column, paragraph 2 -page 153, right-hand column, paragraph 2 ---	6,7
P,X	WO 00 01846 A (MORTIER KATHERINE ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application page 8, line 9 -page 10, line 22 page 12, line 14 -page 23, line 2 figures 5,9; examples 1-4 ---	1-4, 12-21, 23-25, 28-31, 34-39
P,X	WO 00 63425 A (FEICHTINGER RICHARD ;BEGHYN MYRIAM (BE); DEVGEN NV (BE); BOGAERT T) 26 October 2000 (2000-10-26) abstract page 2, line 14-30 page 6, line 18-33 page 7, line 12 -page 9, line 28 page 12, line 20 -page 13, line 25; example 3 ---	2-5,8,9, 29-33
T	TIMMONS LISA ET AL: "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans." GENE (AMSTERDAM), vol. 263, no. 1-2, 2001, pages 103-112, XP001009512 ISSN: 0378-1119 the whole document -----	1-4, 12-21, 23-26, 28-31, 34-39

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

rnational Application No
PCT/EP 00/13149

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0001846 A	13-01-2000	AU 4907999 A	24-01-2000
		EP 1093526 A	25-04-2001
		GB 2349885 A	15-11-2000
		NO 20010019 A	05-03-2001
WO 0063425 A	26-10-2000	AU 3984600 A	02-11-2000
		GB 2351152 A	20-12-2000